Response of the Benign Hypertrophied Prostate to Treatment with an LHRH Analogue

Authors:
Publisher website
Google Scholar
Abstract
Summary— Twenty patients with outflow tract obstruction secondary to benign prostatic hypertrophy were treated with an LHRH analogue, buserelin, for up to 6 months. Despite maintaining castrate levels of testosterone and achieving a significant reduction in tissue levels of dihydrotestosterone, no significant improvement was seen in flow rate or residual volume.